N/A N=8 Randomized Double-blind Treatment

Effectiveness of Prazosin in Bulimic Patients Experiencing Nightmares Due to PTSD

Stress Disorders, Post-Traumatic · Bulimia Nervosa

Bottom Line

View on ClinicalTrials.gov: NCT02382848 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jul 2019

Primary outcome: Primary: Decrease in Frequency of Nightmares Using the Sleep-50 Questionnaire — 2.25; 2.75 score on a scale

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Prazosin (Drug); Placebo (Drug)
Age: Adult · 18+ yrs
Sex: Female
Sponsor: Milton S. Hershey Medical Center
Primary completion: Mar 2018

Outcome Measures

Outcome	Result	p-value
PRIMARY Decrease in Frequency of Nightmares Using the Sleep-50 Questionnaire	2.25; 2.75	—
PRIMARY Decrease in Rapid Eye Movement (REM) Density & Normalization of REM Disruptions	—	—
SECONDARY Decrease in Bulimia Symptoms	43.1; 38.6	—
SECONDARY Decrease in Total CAPS Score (PTSD)	65.5; 79.8	—
SECONDARY Decrease in Depressed Mood as Measured by the HDRS (Hamilton Depression Rating Scale) and Subject Interview	1.4; 1.3	—
SECONDARY Decrease in Self Harm Thoughts as Measured by the HDRS and Subject Interview	0.5; .1	—

Summary

This research is being done to find out how effective Prazosin is in the treatment of bulimic patients experiencing distressing nightmares using subjective and objective measures.

Eligibility Criteria

Inclusion Criteria

Age 18-45
Clinical diagnosis of Bulimia Nervosa with complaint of nightmares secondary to PTSD

Exclusion Criteria

Restless leg syndrome
Narcolepsy
Sleep Apnea
Neurological disorders
Pregnancy
cardiac abnormalities
significant electrolyte abnormalities
Use of steroids, beta blockers, prazosin
Alcohol/substance abuse

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02382848). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.